Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Amazighon Jan 13, 2022 3:18pm
306 Views
Post# 34314128

RE:obsidian.....

RE:obsidian.....
polo22 wrote: tks Amazigh...like my line of credit..lol...now when is the start of  phase one.....and do you have the same prediction 1.30 to 1.50 at the end!!!....


Phase I was announced to be finished in the first quarter of this year, so the start should be any time now. I heard that the ethical commity, which has a big influence on studies on humans - as it should be - gathers only on Wednesdays, making decision making time-consuming. I hope this Wednesday the commity finally gave a go, and otherwise on the next one.
 
As you know on April 26th the B warrants expire, and because they are tradable expiration date will not be extended. Many investors own these warrants and when exercised it will be an extra income of around $8 million dollars. So, before 26th April the SP will and has to be higher than $1.30 ( the exercise price for the B warrants). I believe Bob will make sure the SP reaches this target otherwise CLAS misses this large amount of money and will have many angry investors and insiders. I myself think that when phase I starts the SP will gradually increase and this target of $1.30 will be reached easily.

The SP target I am waiting for is a multiple of $1.30 and we will definitely reach that in 2022.



<< Previous
Bullboard Posts
Next >>